Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English
Novartis Foundation | English
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Giovanni Caforio 
        • Simon Moroney 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Kees Roks 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 
        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 
        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 
      • Medical congresses and events 
        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 
        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 
        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 
      • Technology platforms 
      • Research disease areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 
        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 
        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 
        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation 
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event calendar 
      • Financial data 
        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 
        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 
        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 
        • Corporate governance 
      • Reporting and transparency hub 
        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News archive  
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career search 
      • Our business functions 
        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 
        • Temporary contracts 
      • Early careers 
        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • Surface of an engineered T cell
    Discovery
    CancerCell and Gene TherapyNovartis Institutes for BioMedical ResearchClinical ResearchClinical Trials
    Sep 27, 2021

    Researchers boost understanding of T-cell therapy in blood cancer

    Novartis investigators find genetic explanations for why some young patients relapse.

    Discovery
  • Novartis scientists work side-by-side with a scholar
    Discovery
    DiseasesDrug DiscoveryNovartis Institutes for BioMedical ResearchDrug Development
    Jul 19, 2021

    Teaming up with academia to discover medicines

    The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.

    Discovery
  • Continuous flow manufacturing facility
    Discovery
    Drug DiscoveryEmerging TechnologyInnovationNovartis Institutes for BioMedical ResearchDrug Development
    Jul 16, 2021

    New drug manufacturing tools change pharma chemistry

    The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.

    Discovery
  • Big data reveals new patterns
    Discovery
    Chronic IllnessDigitalDiseasesNovartis Institutes for BioMedical ResearchNew Scientific DiscoveriesScientific Research
    Jul 14, 2021

    Embracing big data to understand complex diseases

    Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.

    Discovery
  • Researchers review visuals markers
    Discovery
    DiseasesDrug DiscoveryNovartis Institutes for BioMedical ResearchScientific ResearchGenetic Disease
    Sep 27, 2021

    Discovery gives cystic fibrosis researchers new direction

    Novartis-Harvard team identifies a new type of cell that is key to the disease.

    Discovery
  • Digital tools in neuroscience
    Discovery
    DigitalDrug DiscoveryNeuroscienceNovartis Institutes for BioMedical ResearchClinical TrialsDrug Development
    Jul 19, 2021

    Quest for a new measure of mental health

    Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.

    Discovery
  • Dr. Luca Finelli demonstrates to his team members the interface of the predictive module Sense on a screen.
    Discovery
    DigitalEmerging TechnologyInnovationReimagine MedicineScientific ResearchDrug Development
    Jul 14, 2021

    Drug development gets big data analytics boost

    With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.

    Discovery
  • Vice President and Head of CAR-T US shares her story for “Women in Science
    Discovery
    OncologyWomen in ScienceWorking at NovartisReimagine MedicineCareers
    Jul 19, 2021

    Women in Science: Kristen Harrington-Smith

    Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

    Discovery
  • Bernardo Bazet Lyonnet begins his search for a new medicine
    Discovery
    Drug DiscoveryInfectious DiseasesInnovationNext Generation ScientistNovartis Institutes for BioMedical Research
    Jul 16, 2021

    Open resources at Novartis help drive innovation

    With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

    Discovery
  • T-cell with active receptors
    Discovery
    CancerNovartis Institutes for BioMedical ResearchOncologyTargeted TherapyClinical Research
    Jul 14, 2021

    Immuno-oncology researchers seek to build smart drug combos

    Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.

    Discovery
  • Vice President of Strategic Data shares her story for “Women in Science.”
    Discovery
    DigitalOncologyWomen in ScienceWorking at NovartisReimagine MedicineCareers
    Jul 19, 2021

    Women in Science: Mimi Huizinga

    Meet our Vice President of Strategic Data and Digital at Novartis Oncology.

    Discovery
  • Circuit board
    Discovery
    DigitalDrug DiscoveryInnovationNovartis Institutes for BioMedical ResearchDrug Development
    Jul 16, 2021

    Machine learning poised to accelerate drug discovery

    Technology used to tag friends on social media could change the way drug discovery is done.

    Discovery

Pagination

  • ‹ Previous page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Eurovision
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience